Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types,
accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E …

Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …

Invasive lobular carcinoma (ILC) accounts for 10% to 15% of breast cancers in the United
States, 80% of which are estrogen receptor (ER)-positive, with an unusual metastatic pattern …

Targeting the PI3K–AKT–mTOR pathway is a promising therapeutic strategy for breast
cancer treatment. However, low response rates and development of resistance to PI3K–AKT …

Simple Summary Invasive lobular breast cancer (ILC) is the second most common
histological subtype of invasive breast cancer, which is noted to have a unique microscopic …

Simple Summary Several clinical protocols are exploring the anticancer effect of
immunotherapy combined to targeted therapy. Indeed, emerging evidence demonstrates …

The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the
outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC) …

Cytomegalovirus (CMV) infection remains a main opportunistic infection after solid organ
transplantation (SOT), challenging both patient and graft outcomes. 1 Yet, despite important …

Abstract Purpose of Review Invasive lobular carcinoma (ILC) is increasingly recognized as a
distinct subtype of breast cancer with unique management challenges. We reviewed …

mTOR regulates several processes that control tumor development, including cancer cell
growth, angiogenesis and the immune response to tumor. Accordingly, mTOR inhibitors …